共 287 条
[41]
Apolone G(2019)Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting mu-opioid receptor antagonist Drug Metab Pharmacokinet 34 126-1053
[42]
van den Beuken-van Everdingen MHHL(2019)A meta-analysis of naldemedine for the treatment of opioid-induced constipation Expert Rev Clin Pharmacol 12 121-208
[43]
Joosten EA(2019)Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label phase III studies J Pain Res 12 127-291
[44]
Tjan-Heijnen VC(2019)Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects Xenobiotica 49 1044-1550
[45]
Janssen DJ(2017)Methylnaltrexone versus naloxone for opioid-induced constipation in the medical intensive care unit Ann Pharmacother 51 203-2396
[46]
Portenoy RK(2007)Evaluation of single oral doses of NKTR118 (PEG-Naloxol) as a peripheral opioid antagonist (POA): a double-blind placebo-controlled study in healthy male subjects J Clin Pharmacol 47 1210-480
[47]
Ganzer H(2017)Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation Journal of Pharmacology and Experimental Therapeutics 361 280-1883
[48]
Touger-Decker R(2013)A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation Pain 154 1542-107
[49]
Byham-Gray L(2014)Naloxegol for opioid-induced constipation in patients with noncancer pain N Engl J Med 370 2387-1266
[50]
Murphy BA(2015)Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response United European Gastroenterol J 3 471-1135